Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 5/20 | 1.00 |
| ▸ | NDUFS8 | O00217 | 5/20 | 1.00 |
| ▸ | COXFA4 | O00483 | 5/20 | 1.00 |
| ▸ | NDUFAB1 | O14561 | 5/20 | 1.00 |
| ▸ | NDUFA1 | O15239 | 5/20 | 1.00 |
| ▸ | NDUFS4 | O43181 | 5/20 | 1.00 |
| ▸ | NDUFB5 | O43674 | 5/20 | 1.00 |
| ▸ | NDUFB3 | O43676 | 5/20 | 1.00 |
| ▸ | NDUFC1 | O43677 | 5/20 | 1.00 |
| ▸ | NDUFA2 | O43678 | 5/20 | 1.00 |
| ▸ | NDUFS5 | O43920 | 5/20 | 1.00 |
| ▸ | NDUFS7 | O75251 | 5/20 | 1.00 |
| ▸ | NDUFS2 | O75306 | 5/20 | 1.00 |
| ▸ | NDUFS6 | O75380 | 5/20 | 1.00 |
| ▸ | NDUFB1 | O75438 | 5/20 | 1.00 |
| ▸ | NDUFS3 | O75489 | 5/20 | 1.00 |
| ▸ | NDUFB6 | O95139 | 5/20 | 1.00 |
| ▸ | NDUFA3 | O95167 | 5/20 | 1.00 |
| ▸ | NDUFB4 | O95168 | 5/20 | 1.00 |
| ▸ | NDUFB8 | O95169 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Auraptene SCHEMBL2535034 | 1.00 | ALOX15 (1.00) | ALOX15NDUFS8COXFA4NDUFAB1NDUFA1 | |
| Umbelliprenin SCHEMBL28133292 | 0.99 | ALOX15 (1.00) | ALOX15NDUFS8COXFA4NDUFAB1NDUFA1 | |
| Umbelliprenin SCHEMBL18265478 | 0.99 | ALOX15 (1.00) | ALOX15NDUFS8COXFA4NDUFAB1NDUFA1 | |
| Umbelliprenin SCHEMBL26641528 | 0.99 | ALOX15 (1.00) | ALOX15NDUFS8COXFA4NDUFAB1NDUFA1 | |
| SCHEMBL17898120 | 0.92 | ALOX15 (1.00) | ALOX15NDUFS8COXFA4NDUFAB1NDUFA1 | |
| SCHEMBL17898118 | 0.92 | ALOX15 (1.00) | ALOX15NDUFS8COXFA4NDUFAB1NDUFA1 | |
| SCHEMBL17898119 | 0.91 | ALOX15 (1.00) | ALOX15NDUFS8COXFA4NDUFAB1NDUFA1 | |
| SCHEMBL17898115 | 0.91 | ALOX15 (1.00) | ALOX15NDUFS8COXFA4NDUFAB1NDUFA1 | |
| SCHEMBL17898114 | 0.91 | ALOX15 (1.00) | ALOX15NDUFS8COXFA4NDUFAB1NDUFA1 | |
| SCHEMBL17898117 | 0.91 | ALOX15 (1.00) | ALOX15NDUFS8COXFA4NDUFAB1NDUFA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714440-A2 | A HEALING HERBAL-MINERAL COMPOSITION WITH ENHANCED EFFECTS | Kurek, Janusz (PL) | 2026-03-25 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| EP-4580612-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-07-09 | — | — | EP | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| WO-2024172325-A1 | COMPOSITION CONTAINING PONCIRI FRUCTUS EXTRACT FOR PREVENTING OR TREATING MUSCLE DISEASE | 한국과학기술연구원 | 2024-08-22 | — | — | WO | claimed |
| CN-118344322-A | Method for separating high-purity auraptene from ferula gum | 上海致臻志臣科技有限公司 | 2024-07-16 | — | — | CN | claimed |
| WO-2024047248-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-03-07 | — | — | WO | claimed |
| CN-116577437-A | Method for measuring content of effective components of immature bitter orange | 泸州市市场检验检测中心 | 2023-08-11 | — | — | CN | claimed |
| CN-116548270-A | Method for promoting anthurium to release monoterpene beta-ocimene | 玉林师范学院 | 2023-08-08 | — | — | CN | claimed |
| US-20230101403-A1 | METHOD OF TREATING OR AMELIORATING CANCERS DRIVEN BY RECEPTOR TYROSINE KINASE FUSION ONCOGENES, AND COMPOSITIONS FOR THE SAME | UNIV PENNSYLVANIA (US) | 2023-03-30 | — | — | US | claimed |
| CN-112852733-B | Application of levisticin A in preparation of medicine for in vitro amplification of human hematopoietic stem cells | 南开大学 | 2022-11-25 | — | — | CN | claimed |
| EP-4072558-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION WITH STEROIDS AND A MODULATOR | Buzzelet Development And Technologies Ltd (IL) | 2022-10-19 | — | — | EP | claimed |
| CN-114874199-A | Method for simultaneously preparing epoxy auraptene and epoxy bergamottin | 集美大学 | 2022-08-09 | — | — | CN | claimed |
| US-11266626-B2 | Reduction of ER-MAM-localized APP-C99 and methods of treating alzheimer's disease | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-03-08 | — | — | US | claimed |
| EP-3324951-B1 | PERITONEAL THERAPEUTIC FLUID | OPTERION HEALTH AG (CH) | 2021-05-26 | — | — | EP | claimed |
| EP-3347486-A2 | REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHODS OF TREATING ALZHEIMER'S DISEASE | The Trustees of Columbia University in the City of New York (US) | 2018-07-18 | — | — | EP | claimed |
| WO-2017044807-A2 | REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHODS OF TREATING ALZHEIMER'S DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-03-16 | — | — | WO | claimed |
| US-20070293563-A1 | Novel Agents for Preventing and Treating Disorders Connected to Impaired Neurotransmission | DSM IP ASSETS B.V. (NL) | 2007-12-20 | — | — | US | claimed |
| EP-1802298-A2 | NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSMIP Assets B.V. (NL) | 2007-07-04 | — | — | EP | claimed |
| WO-2006042441-A2 | NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSM IP ASSETS B.V. (NL) | 2006-04-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293563-A1 | Novel Agents for Preventing and Treating Disorders Connected to Impaired Neurotransmission | CHRNA2, CHRM1, CHRM5 | ALOX15 1107/4885NDUFS8 649/4885COXFA4 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.